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Atrioventricular septal defects (AVSD) are common cardiovascular malformations, occurring in 3.5/10,000 births.
Although frequently associated with trisomy 21, autosomal dominant AVSD has also been described. Recently we
identified and characterized the cell adhesion molecule CRELD1 (previously known as “cirrin”) as a candidate
gene for the AVSD2 locus mapping to chromosome 3p25. Analysis of the CRELD1 gene from individuals with
non–trisomy 21–associated AVSD identified heterozygous missense mutations in nearly 6% of this population,
including mutations in isolated AVSD and AVSD associated with heterotaxy syndrome. CRELD1 is the first human
gene to be implicated in the pathogenesis of isolated AVSD and AVSD in the context of heterotaxy, which provides
an important step in unraveling the pathogenesis of AVSD.
Congenital heart malformations are the most common
form of birth defect, occurring in ∼1% of live births.
Atrioventricular septal defects (AVSD) are a subset of
malformations that constitute 7.4% of all recognized
congenital heart defects (Ferencz et al. 1997). The for-
mation of the atrioventricular septa and valves from pro-
genitor cardiac structures called “endocardial cushions”
is required to produce the normal four-chambered heart
(Eisenberg and Markwald 1995). During atrioventric-
ular valvuloseptal morphogenesis, the endocardial cush-
ions expand as they are infiltrated by extracellular ma-
trix secreted from the surrounding myocardium. The
cushions then fuse and are remodeled to form the atrio-
ventricular valves and septa (Markwald et al. 1981; Ei-
senberg and Markwald 1995). Failure of this process
results in AVSD, with the degree of severity dependent
on the stage at which the developmental failure occurs
(Wessels and Markwald 2000).
AVSD are a spectrum of cardiac malformations that
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result in a persistent common atrioventricular canal (Ja-
cobs et al. 2000). The complete form of AVSD involves
underdevelopment of the lower part of the atrial septum
and the upper part of the ventricular septum. There is
also a single common atrioventricular valve that results
in unrestricted circulatory communication between the
atria and ventricles. A less severe form, known as “par-
tial AVSD” or “ostium primum atrial septal defect,” has
a deficiency of the atrial septum. Defects of the inlet
muscular ventricular septum and isolated cleft mitral
valve are also considered to be part of the AVSD clinical
spectrum. Complete AVSD are clinically apparent at birth,
whereas less severe forms, such as an isolated cleft mitral
valve or small defects of the atrial or ventricular septa,
may go undetected.
AVSD are most frequently associated with trisomy 21,
but there is considerable evidence for genetic heteroge-
neity. There are several other syndromes that can have
AVSD as a clinical finding, including Ivemark syndrome
(MIM 208530), 3p syndrome (MIM 606217), auto-
somal heterotaxy syndrome (MIM 605376), Ellis-van
Creveld syndrome (MIM 225500), CHARGE syndrome
(MIM 214800), and Kaufman-McKusick syndrome
(MIM 236700). In addition to syndromic AVSD, several
large families with isolated AVSD inherited in an au-
tosomal dominant pattern with incomplete penetrance
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Table 1
Clinical and Molecular Findings in Patients with AVSD
Phenotype
No. of Subjects with
Nucleotide Change
Nucleotide
Change and
Position Amino Acid Change
Complete AVSD ( )np 13 0
Partial AVSD (ostium primum ASD) ( )np 22 2 C4148T, exon 9 T311I
C4201T, exon 9 R329C
AVSD and hypoplastic arch ( )np 1 0
AVSD and COAa ( )np 2 0
Partial AVSD and DORVb ( )np 1 0
Partial AVSD and heterotaxy ( )np 11 1 G1566A, exon 3 R107H
a COA p coarctation of the aorta.
b DORV p double-outlet right ventricle.
and variable expression have been described (O’Nuallain
et al. 1977; Emanuel et al. 1983; Wilson et al. 1993;
Cousineau et al. 1994; Kumar et al. 1994; Amati et al.
1995). Study of one large family resulted in the identi-
fication of the AVSD1 locus on chromosome 1p31-p21
(MIM 606215) by use of a combination of DNA pooling
and shared segment analysis in a high-density genome
screen (Sheffield et al. 1997). Although the responsible
gene has not yet been identified, that study demonstrated
the existence of a congenital heart defect susceptibility
gene inherited as an autosomal dominant trait with in-
complete penetrance.
A second AVSD locus, AVSD2 (MIM 606217), was
defined through analysis of chromosomal breakpoints
in 3p syndrome, which results from a deletion of 3p25-
pter (Phipps et al. 1994; Drumheller et al. 1996; Green
et al. 2000). The features of this syndrome include de-
velopmental delay, microcephaly, ptosis, telecanthus, and
micrognathia. Variable features that are presumably due
to differences in proximal breakpoints include postaxial
polydactyly, renal and gastrointestinal abnormalities, cleft
palate, and congenital heart defects. Congenital heart de-
fects occur in approximately one-third of individuals
with 3p syndrome and are typically AVSD (Green et
al. 2000). Complete AVSD has been described in at least
one individual (Ramer et al. 1989). Ventricular septal
defects and atrial septal defects have also been associated
with 3p syndrome (Phipps et al. 1994).
From these data, it is clear that there is a substantial
amount of genetic heterogeneity, incomplete penetrance,
and variable expression associated with AVSD, increasing
the difficulty of finding the susceptibility genes. In fact,
the majority of AVSD not related to trisomy 21 occur
as sporadic cases of isolated AVSD (Digilio et al. 1999).
The relatively high incidence of sporadic versus familial
cases indicates that isolated AVSD is usually genetically
complex, with multiple factors contributing to suscep-
tibility and variability of expression.
We recently identified a novel cell adhesion molecule,
CRELD1 (GenBank accession number AF452623), as a
candidate for the AVSD2 locus, on the basis of its map-
ping to chromosome 3p25 and its expression in the de-
veloping heart (Rupp et al. 2002). To test the hypothesis
that mutation ofCRELD1 is associated with non–trisomy
21–related AVSD, we analyzed a group of subjects with
complete or partial AVSD for CRELD1 mutations. Sub-
jects for this study were recruited through the Oregon
Registry of Congenital Heart Defects or by an approved
protocol for the investigation of congenital heart disease
through The Children’s Hospital of Philadelphia. All
studies were done with informed consent and conformed
to institutional guidelines. We screened 50 unrelated sub-
jects with AVSD and no known cytogenetic abnormal-
ities. The specific phenotypes are listed in table 1. With
the exception of the group with heterotaxy, the subjects
did not have extracardiac abnormalities. Samples for
DNA sequencing were prepared by PCR amplification
of fragments encompassing each of the 10 major coding
exons of CRELD1, including 50 bp of each flanking
intron.
A single-base change, C4201T, was identified in one
individual (subject 1) with an isolated partial AVSD (fig.
1a). The mutation results in a substitution of cysteine
for arginine at amino acid 329 (R329C) in the second
cb-EGF domain (fig. 1b). The addition of a free cysteine
residue to a cb-EGF domain is predicted to disrupt the
disulfide-bonding pattern for that domain. Another het-
erozygous CrT transition in exon 9, C4148T, was de-
tected in an unrelated individual (subject 2), also with
an isolated partial AVSD (fig. 1a). The C4148T change
results in a substitution of isoleucine for threonine at
amino acid 311 (T311I) and in the second cb-EGF domain
(fig. 1b). These alterations were not detected in 400 nor-
mal chromosomes from a North American white control
population, which is representative of the subjects’ racial
background.
A third heterozygous missense mutation was detected
in an individual with a partial AVSD and evidence of
heterotaxy syndrome. In addition to the partial AVSD,
this individual had dextrocardia, right ventricle aorta with
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Figure 1 a, Sequence analyses identifying missense mutations in CRELD1. The arrows on each electropherogram indicate the variant
nucleotides, with the wild-type sequence shown below. The altered nucleotides are shown in green. The single-letter–amino acid translation is
under the first base of each codon. The altered amino acid residues are in red. Sequences from the complementary strands showed the same
heterozygous changes. b, Diagrammatic representation of CRELD1 protein. The approximate positions of the amino acid changes are indicated
above the diagram of CRELD1, with arrowheads pointing to the position of the substituted amino acid. c, Alignment of the sequence for the
cb-EGF domain from the human, mouse, and bovine CRELD1 genes. d, Alignment of partial sequence of the WE domain from the human,
mouse, and bovine CRELD1 genes. Amino acids that are identical among the three species are highlighted in green. The amino acid residues
changed by the missense mutations in humans are boxed.
pulmonary atresia, and a right aortic arch. No extracar-
diac abnormalities were detected. The single-base GrA
substitution, G1566A, is in exon 3 and results in a sub-
stitution of histidine for arginine (R107H) in the highly
conserved WE domain (fig. 1a and 1b). This subject is of
mixed Hispanic and African American descent. The base
substitution was not detected in 200 chromosomes from
an African American control population or in 100 chro-
mosomes from a Hispanic control population.
The R329C, T311I, and R107H mutations affect
highly conserved residues and result in nonconservative
changes in amino acid sequence (fig. 1c and 1d). In each
case, the gene was sequenced in its entirety, and no ad-
ditional mutations were found, indicating that these mu-
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Figure 2 Diagrammatic representation of the cb-EGF domain
harboring the T311I and R329C mutations. Conserved amino acid
residues defining cb-EGF domains are indicated by the single-letter–
amino acid code. Black lines show the disulfide-bonding pattern for
the conserved cysteine residues. The positions of mutated amino acid
residues are indicated by black circles; the b-hydroxylated asparagine
residue is indicated by an asterisk.
Figure 3 a, Western blot showing the mobility shift of the C329
mutant protein, compared with wild-type (wt) CRELD1 without
PNGase F digestion. Duplicate samples are loaded in alternating lanes.
Digestion of the proteins with PNGase F results in a slight increase in
mobility, compared with undigested protein, but does not resolve the
difference in mobility between wt and C329 CRELD1. b, Western blot
showing digestion of wt and 329C CRELD1 with PNGase F alone
() or a mixture of glycohydrolases (PNGase F, sialidase A, endo-O-
glycosidase, b(1,4)galactosidase, and glucosaminidase) that cleave all
glycosidase linkages (), compared with undigested protein ().
Note that digestion with additional glycohydrolases does not further
shift the protein band, compared with digestion with PNGase F, in-
dicating that CRELD1 is N-glycosylated but does not have other gly-
cosylation sites to account for the decreased mobility of C329, com-
pared with wt protein.
tations act in a dominant fashion. In addition, the range
of phenotypes associated with mutations in the present
study demonstrates considerable variability of expres-
sion for CRELD1 mutations.
Family members of subject 1 were available for study.
Analysis of genomic DNA from the first-degree relatives
showed inheritance of the R329C mutation (allele T4201)
from the father. A brother and sister of the subject also
carry the T4201 allele, although none of these family
members reported having a heart defect. Two-dimen-
sional echocardiography and color flow Doppler studies
were performed on the parents and carrier sister of the
proband. In each case, the studies showed that these
individuals had structurally normal hearts with normal
ventricular function and no evidence of congenital heart
disease (data not shown). As has previously been ob-
served in AVSD, these findings are consistent with in-
complete penetrance (Pierpont et al. 2000). Given the
low penetrance observed in this family, we propose that
CRELD1 is an AVSD-susceptibility gene and that
CRELD1 mutations increase the risk of developing a
heart defect, rather than being directly causative.
The two mutations associated with isolated partial
AVSD occurred in a cb-EGF domain (fig. 2). This type
of domain is prevalent in many extracellular proteins,
and heterozygous mutations affecting cb-EGF domains
have been associated with a number of genetic disorders.
Of particular interest, arginine-to-cysteine and threo-
nine-to-isoleucine substitutions in cb-EGF domains have
been noted in hemophilia B, Marfan syndrome, familial
hypercholesterolemia, and heterotaxy due to CFC1 mu-
tations (Krawczak and Cooper 1997; Collod-Beroud et
al. 1998; Bamford et al. 2000).
It was anticipated that the introduction of a free cys-
teine by the R329C mutation would disrupt protein struc-
ture. To determine if the R329C substitution altered char-
acteristics of CRELD1, we expressed the wild-type or
mutant allele with a carboxyl-terminal FLAG-epitope
tag in stably transfected HEK 293 cells and visualized
the protein by western blot analysis. Mobility of the
C329 mutant protein was slightly retarded, compared
with that of wild-type CRELD1 on SDS-PAGE in the
presence of reducing agents (fig. 3a). The amino acid
substitution alone does not explain an apparent differ-
ence in molecular weight but could result in altered post-
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translational modification or a change in protein con-
formation. Digestion with N-glycosidase F prior to
SDS-PAGE increased the mobility of both the wild-type
and C329 protein but did not alter the difference in
mobility between the two molecules (fig. 3a). The data
demonstrate that CRELD1 is N-glycosylated, as was
predicted by the presence of two N-glycosylation con-
sensus sites (Rupp et al. 2002), but also that the altered
mobility is not due to exposure of additional N-glyco-
sylation sites. Digestion with a mixture of glycohydro-
lases did not resolve the difference in mobility between
the normal and mutant molecule, indicating that the
discrepancy is not due to alteration of any common form
of glycosylation (fig. 3b).
cb-EGF domains are posttranslationally modified to
contain a b-hydroxylated asparagine or aspartate residue
in the calcium-binding region. Treatment of stably trans-
fected cells with 10 mM 2,2′-dipyridyl, an inhibitor of
b-hydroxylase, for 24 h did not alter the mobility of the
C329 protein, indicating that a change in b-hydroxylation
was not the cause of the shift in mobility (data not
shown). Further analysis will be required to determine the
cause of the altered mobility of the C329 mutant protein.
We conclude that the missense changes described here
represent disease-related mutations of CRELD1 in these
subjects. None of the mutations were found in a mini-
mum of 100 control chromosomes, indicating a specific
association with AVSD. The mutations we have identified
to date are all associated with partial AVSD, occurring in
nearly 9% of that population. It is possible that CRELD1
mutations are not associated with complete AVSD, al-
though analysis of a larger complete AVSD population
is required. CRELD1 is the first human gene to be di-
rectly associated with AVSD. The cell adhesion molecule
DSCAM has been identified as a candidate gene for tri-
somy 21–related AVSD (Barlow et al. 2001), but, to date,
no DSCAM mutations have been reported. The identi-
fication of mutations in CRELD1 associated with AVSD
highlight the importance of cell adhesion in valvulosep-
tal morphogenesis. Furthermore, this study suggests that
isolated AVSD may share a common genetic etiology
with AVSD associated with heterotaxy syndrome, al-
though study of additional heterotaxy subjects is needed
for confirmation. This is analogous to CFC1 mutations,
where loss of function has been associated with left-right
laterality defects with heart malformations (Bamford et
al. 2000), as well as isolated transposition of the great
arteries or double-outlet right ventricle (Goldmuntz et
al. 2002). Our study shows that CRELD1 plays an im-
portant role in normal and abnormal valvuloseptal mor-
phogenesis and that mutations that affect CRELD1
structure predispose to AVSD. Identification of a gene
involved in the pathogenesis of AVSD provides new in-
sight into a biochemical pathway that is important in
the correct formation of the atrioventricular valves and
septa.
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